European Companies Search Engine
EU funding (€6,223,330): Integrating Epidemiology and Experimental Biology to Improve Risk Assessment of Exposure to Mixtures of Endocrine Disruptive Compounds Hor 1 May 2015 EU Research and Innovation programme "Horizon"
Overview
Text
Integrating Epidemiology and Experimental Biology to Improve Risk Assessment of Exposure to Mixtures of Endocrine Disruptive Compounds
A large body of evidence supports associations between exposure to anthropogenic chemicals and endocrine disruptive effects, leading to disorders in humans and wildlife. Based on the scientific documentation it is beyond doubt that endocrine disrupting chemicals (EDCs) are of concern and need to be handled according to the risks they pose, as single chemicals or as mixtures. To develop chemical risk assessment to respond to these concerns, there is an urgent need to improve our understanding of the mechanisms and health effects of EDCs, in particular in mixtures. This will require selection, refinement and development of tools for assessment of EDC mixtures to bring current risk assessment procedures to a level where they can support risk management. This project is designed to promote the use of safe chemicals for the next generation. EDC-MixRisk aims to meet the societal need for improved decision-making regarding human exposure risks to mixtures of EDCs. EDC-MixRisk will determine risks for multiple adverse health outcomes based on molecular mechanisms involved after early life exposure to EDC mixtures. The task is approached through interdisciplinary cooperation between experts in epidemiology, experimental toxicology and molecular biology, and risk assessment. The value of this combined research effort is: i) Identification of EDC mixtures that are associated with multiple adverse health outcomes in three health domains (growth and metabolism, neurodevelopment and sexual development) in epidemiology; ii) Identification of molecular mechanisms and pathways underlying the associations between exposure and adverse health outcomes by the use and development of state-of-the-art experimental models and iii) Development of a transparent and systematic framework in risk assessment for integrating epidemiological and experimental research to facilitate the assessment of risk and societal impact, thus promoting better risk management for EDCs and their mixtures.
Funded Companies:
| Company name | Funding amount |
| Centre National de la Recherche Scientifique CNRS | €428,436 |
| Ethniko Kai Kapodistriako Panepistimio Athinon | €321,250 |
| Goeteborgs Universitet | €316,750 |
| Icahn School OF Medicine AT Mount Sinai | €265,570 |
| Istituto Europeo Di Oncologia Srl | €489,000 |
| Karlstads Universitet | €1,194,481 |
| Karolinska Institutet | €1,089,181 |
| Lunds Universitet | €585,000 |
| Museum National d'Histoire Naturelle | €0.00 |
| Orebro University | €252,030 |
| Stockholms Universitet | €450,061 |
| Terveyden JA Hyvinvoinnin Laitos | €350,538 |
| Universitaet Leipzig | €62,500 |
| Uppsala Universitet | €418,533 |
Source: https://cordis.europa.eu/project/id/634880
The filing refers to a past date, and does not necessarily reflect the current state.